Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTrials.gov. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Status: ACTIVE_NOT_RECRUITING